Papel actual de los inmunomoduladores convencionales en la enfermedad inflamatoria intestinal pediátrica

Pediatric Inflammatory Bowel Disease (P-IBD) has its own characteristics and early, intensive and sustained treatment is recommended. Immunomodulator treatment is indicated for maintenance of remission in P-CD (Pediatric Crohn's Disesase) treated with exclusive enteral nutrition (EEN) to induce remission and P-UC (Pediatric Ulcerative Colitis) that requires steroids to induce remission. Combo therapy is recommended for patients at high risk of complications; however, individualized treatment and the assessment of adverse events is mandatory. By now, the use of thiopurines is not justified for the prevention of loss of response to anti-TNF and antibody formation. Larger pediatric prospective studies are needed.